Sugi Predict

Sugi Predict / Compounds / SCHEMBL23043385

SCHEMBL23043385

SCHEMBL23043385

Nc1c(Br)cc(Br)c2c(Cl)cccc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HKDC1 Q2TB90 1/20 0.58
▸ CASP6 P55212 1/20 0.42
▸ NR4A2 P43354 3/20 0.41
▸ CYP1A2 P05177 2/20 0.39
▸ CYP2A6 P11509 2/20 0.39
▸ CTSB P07858 1/20 0.39
▸ CHEK1 O14757 1/20 0.35
▸ FLT3 P36888 1/20 0.35
▸ PLK3 Q9H4B4 1/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CA2 P00918 1/20 0.35
▸ CA9 Q16790 1/20 0.35
▸ GAA P10253 2/20 0.34
▸ MAPT P10636 1/20 0.33
▸ ACHE P22303 1/20 0.33
▸ AHR P35869 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ CSNK2A2 P19784 2/20 0.32
▸ CSNK2B P67870 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29418744 1.00 HKDC1 (0.58) HKDC1CASP6NR4A2CYP1A2CYP2A6
SCHEMBL29937238 0.89 HKDC1 (0.49) HKDC1CASP6NR4A2CYP1A2CYP2A6
SCHEMBL29344203 0.89 HKDC1 (0.49) HKDC1CASP6NR4A2CYP1A2CYP2A6
SCHEMBL29943610 0.85 HKDC1 (0.44) HKDC1CASP6NR4A2CYP1A2CYP2A6
SCHEMBL31178562 0.84 HKDC1 (0.45) HKDC1CASP6NR4A2CYP1A2CYP2A6
SCHEMBL29345960 0.84 HKDC1 (0.45) HKDC1CASP6NR4A2CYP1A2CYP2A6
SCHEMBL25894963 0.82 HKDC1 (0.44) HKDC1CASP6NR4A2CYP1A2CYP2A6
SCHEMBL23409303 0.82 HKDC1 (0.58) HKDC1CASP6CTSBCA1CA2
SCHEMBL23043391 0.77 HKDC1 (0.53) HKDC1CASP6CYP1A2CTSBCA1
SCHEMBL29940073 0.77 HKDC1 (0.53) HKDC1CASP6CYP1A2CTSBCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630566-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2026-05-19 — — US disclosed
US-20260109714-A1 PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF GENFLEET THERAPEUTICS SHANGHAI INC (CN) 2026-04-23 — — US disclosed
EP-4216951-B1 KRAS G12D INHIBITORS MIRATI THERAPEUTICS INC (US) 2026-04-01 — — EP disclosed
US-20250340548-A1 KRAS G12C INHIBITORS FRONTIER MEDICINES CORP (US) 2025-11-06 — — US disclosed
EP-4592295-A1 PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF Genfleet Therapeutics (Shanghai) Inc. (CN) 2025-07-30 — — EP disclosed
US-20250206732-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS ARVINAS OPERATIONS, INC. 2025-06-26 — — US disclosed
US-20250154156-A1 QUINAZOLINE DERIVATIVE AS KRAS G12C MUTATION INHIBITOR SHENZHEN FORWARD PHARMACEUTICALS CO., LIMITED (CN) 2025-05-15 — — US disclosed
US-12291539-B2 KRAS G12C inhibitors FRONTIER MEDICINES CORPORATION (US) 2025-05-06 — — US disclosed
US-20250059205-A1 Heterocyclic Compounds and Methods of Use AMGEN INC. (US) 2025-02-20 — — US disclosed
US-20250019387-A1 KRAS G12C INHIBITORS FRONTIER MEDICINES CORPORATION 2025-01-16 — — US disclosed
US-20230077225-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. 2023-03-09 — — US disclosed
WO-2022247770-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海璎黎药业有限公司 2022-12-01 — — WO disclosed
WO-2022232331-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2022-11-03 — — WO disclosed
US-11453683-B1 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2022-09-27 — — US disclosed
EP-4021444-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2022-07-06 — — EP disclosed
CN-114615981-A KRAS G12D inhibitors 米拉蒂治疗股份有限公司 2022-06-10 — — CN disclosed
WO-2022098625-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2022-05-12 — — WO disclosed
WO-2022066646-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2022-03-31 — — WO disclosed
WO-2021041671-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2021-03-04 — — WO disclosed
WO-2021041671-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2021-03-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230077225-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS HKDC1 373/4885CASP6 2978/4885NR4A2 4022/4885
US-12630566-B2 KRas G12D inhibitors KRAS, NRAS, HRAS HKDC1 1097/4885CASP6 3196/4885NR4A2 4644/4885
US-20260109714-A1 PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF KRAS, NRAS, HRAS HKDC1 1518/4885CASP6 3713/4885NR4A2 338/4885
US-20250059205-A1 Heterocyclic Compounds and Methods of Use KRAS, NRAS, HRAS HKDC1 234/4885CASP6 3136/4885NR4A2 3928/4885
US-12291539-B2 KRAS G12C inhibitors KRAS, NRAS, HRAS HKDC1 1488/4885CASP6 2794/4885NR4A2 3217/4885
US-20250340548-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS HKDC1 1488/4885CASP6 2794/4885NR4A2 3217/4885
US-20250206732-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS KRAS, MDM2, VHL HKDC1 2933/4885CASP6 1918/4885NR4A2 3372/4885
US-11453683-B1 KRas G12D inhibitors KRAS, NRAS, HRAS HKDC1 481/4885CASP6 3384/4885NR4A2 4191/4885
US-20250019387-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS HKDC1 1488/4885CASP6 2794/4885NR4A2 3217/4885
US-20250154156-A1 QUINAZOLINE DERIVATIVE AS KRAS G12C MUTATION INHIBITOR KRAS, NRAS, HRAS HKDC1 456/4885CASP6 4112/4885NR4A2 3989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.